Letters to the Editor

Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA;
Dpt. of Clinical studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic;
Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic;
Brno University of Technology, Centre of Excellence IT4Innovations, Brno, Czech Republic;
Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic;
Dpt. of Clinical studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic;
Department of Biology and Ecology, Faculty of Science, University of Ostrava, Czech Republic;
Dpt. of Clinical studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic;
Dept. of Hematology and Cancer Prevention, Medical University of Silesia in Katowice, Poland;
Dept. of Hematology and Cancer Prevention, Medical University of Silesia in Katowice, Poland;
Department of Haematology, Oncology and Internal Diseases, Medical University of Warsaw, Poland;
Department of Haematology, Oncology and Internal Diseases, Medical University of Warsaw, Poland;
Charles University Hospital Pilsen, Czech Republic;
Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom;
Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic;
IT4Innovations, VSB, Technical University of Ostrava, Ostrava, Czech Republic;
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Czech Republic;
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Czech Republic;
Department of Haematology and Transfusiology, University Hospital Bratislava, Slovakia;
Department of Haematology and Transfusiology, University Hospital Bratislava, Slovakia;
Dept. of Haematology ‎& Stem Cell Transplantation, South Pest Central Hospital, Budapest, Hungary;
Department of Haematology, Medical University of Lodz, Copernicus Memorial Hospital, Łódź, Poland;
Dept. and Clinic of Haematology, Blood Neoplasms, Wroclaw Medical University, Poland;
Dept. and Clinic of Haematology, Blood Neoplasms, Wroclaw Medical University, Poland;
Dept. and Clinic of Haematology, Blood Neoplasms, Wroclaw Medical University, Poland;
Jagiellonian University Medical College, Cracow, Poland;
Silesian Hospital Opava, Opava, Czech Republic;
Dpt. of Medicine, Multiple Myeloma Research Perlmutter Cancer Center, NYU School of Medicine, USA;
Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic;
RECETOX, Faculty of Science, Masaryk university in Brno, Brno, Czech Republic
Dpt. of Clinical studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic;
Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic;
Dpt. of Clinical studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic;
Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic;
Haematologica Early view May 7, 2020 https://doi.org/10.3324/haematol.2019.239756